by Swarajya Staff - May 3, 2021 08:17 AM
Merck Pharma
Snapshot
Molnupiravir is currently undergoing a phase-3 trial for the treatment of non-hospitalised patients with confirmed Covid-19.
An experimental oral antiviral drug called molnupiravir, manufactured by the American pharmaceutical company, Merck, is expected to help stem the cases of coronavirus in India.
The company, which is also known as MSD outside the United States and Canada, announced earlier last week that it has entered into non-exclusive voluntary licensing agreements for the drug with five established Indian generics manufacturers.
Even though there are two Covid-19 vaccines in IndiaâCovaxin and Covishieldâ it is believed that molnupiravir would play a key role in fighting the massive health crisis in the country.